---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Care management intervention strategies"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Care management intervention strategies. Topics: FDA direction to use the Spravato REMS as a template, Spravato REMS requirements named as the template, Session monitoring: FDA guidance and company plans, FDA guidance on postmarketing risk mitigation and the psychotherapy component, and 9 further topics. 13 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### FDA direction to use the Spravato REMS as a template

> “the FDA directed us to use the SPRAVATO REMS as a template”
> “we expect there to be training content within the REMS that will take about one to two hours to review.”
> “From a site side, this will be very consistent with what they are already doing for SPRAVATO, outside of a couple of small tweaks that would be specific to the molecule itself, like the six hours versus two hours requirement.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “For instance, we believe that COMP360, if approved, would be subject to a REMS program, under the applicable FDA regulations.”
> “REMS programs are costly and time-consuming for providers to comply with, involving high administrative burden, which could delay or limit our ability to commercialize our investigational COMP360 psilocybin treatment.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-2.2.2.4-2"></a>

### Spravato REMS requirements named as the template

> “Healthcare settings must be certified in the program and ensure that SPRAVATO is:”
> “Only dispensed and administered in healthcare settings.”
> “Patients treated in outpatient settings (e.g. medical offices and clinics) must be enrolled in the program.”
> “Administered by patients under the direct observation of a healthcare provider and that patients are monitored by a healthcare provider for at least 2 hours after administration of SPRAVATO”
> “Pharmacies must be certified in the REMS and must only dispense SPRAVATO to healthcare settings that are certified in the program.”

Source: [Spravato prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf)

<a id="topic-2.2.2.4-3"></a>

### Session monitoring: FDA guidance and company plans

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

> “our design matches what they have guided, which is to have one primary monitor and to use CCTV to assist with the total monitoring by two total healthcare providers.”
> “we would certainly anticipate that the final requirements will be no more stringent than what has been required so far in clinical trials.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.4-4"></a>

### FDA guidance on postmarketing risk mitigation and the psychotherapy component

> “Sponsors should consider the potential need for a risk evaluation and mitigation strategy or additional safety studies that may be required in the postmarketing setting when preparing and submitting a marketing application.”
> “As of the publication date of this guidance, the contribution of the psychotherapy component to any efficacy observed with psychedelic drug treatment has not been characterized.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.4-5"></a>

### Three-phase psychological support model used in COMP360 trials

> “Our trial protocols provide that such support is delivered over three different phases: preparation, the COMP360 administration session, and post-administration follow-up.”
> “A COMP360 administration session lasts approximately six to eight hours and at least one healthcare professional is present throughout the session to monitor and safeguard participants in our clinical trials.”
> “After the acute effects of psilocybin subside, patients are evaluated for safety and discharged.”
> “In our clinical trials, healthcare professionals refrain from intervening with the patient’s experience, unless required for safety reasons.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “The authors also outline the therapist training, mentoring, and fidelity assessment programs they have developed to ensure the quality and consistency of the CPSM delivery.”

Source: [Kirlić et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39741434/)

> “Training consists of four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and participation in webinars.”
> “As part of the phase IIb study of psilocybin therapy for treatment-resistant depression, 65 health care professionals have been fully trained as therapists and assisting therapists, across the US, Canada and Europe.”

Source: [Tai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7908919/)

<a id="topic-2.2.2.4-6"></a>

### Non-directive support during the administration session

> “Speech by either party during the administration sessions was rare; on average, 78% of the time was filled with silence, compared to 25% to 30% in non-administration sessions.”

Source: [Dougherty et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42460632/)

> “It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy.”
> “Support strategies include breath and body awareness, short verbal cues, and physical proximity.”

Source: [COMPASS Pathways support model publication release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx)

> “Extrapolation from the trial setting to clinical practice or the plan to provide specific training to therapists needs to be addressed.”

Source: [EMA (2025)](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression-revision-3_en.pdf)

<a id="topic-2.2.2.4-7"></a>

### Company site-readiness and patient support programs

> “At approval, focus will be on site preparedness – including training, education, REMS certification, assistance with reimbursement and patient support”

Source: [COMPASS Pathways second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000059/q22026pressrelease.htm)

> “We will also have a dedicated team of specialists working directly with clinics to facilitate the logistics associated with reimbursement for both the drug and the monitoring time for COMP360 administration.”
> “we will have patient support programs in place to ensure that affordability is not a barrier to access in the early days of the launch.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-2.2.2.4-8"></a>

### Payer coverage criteria and reauthorization proposed for psilocybin

> “All payer participants agreed that coverage criteria would align with the FDA-approved product label including, for instance, the quantity and frequency of treatment, and would comply with the REMS requirements.”
> “Several added they would look to previous experience with esketamine for guidance and that coverage criteria for psilocybin may be similar.”
> “Whereas some participants would accept provider attestation for continuation of therapy, others would require documentation of improvement and sustained treatment response.”
> “One PBM participant suggested that reviewing claims for other TRD treatments subsequent to psilocybin administration could further support determination of treatment response.”
> “Participants discussed reimbursement considerations with coverage of psilocybin including developing a bundled payment model combining all related services (eg, medication, administration, psychotherapy) into a single billable episode of care”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.4-9"></a>

### Network adequacy and workforce

> “Participants identified the shortage of qualified mental health professionals, both in general and as part of their organizations’ networks, as a primary challenge with equitable access to psilocybin treatment and post-treatment care.”
> “Participants expressed concern related to the potential requirements for equitable access to specialized administration sites because the number of these may be limited, especially in rural areas.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

<a id="topic-2.2.2.4-10"></a>

### State-licensed psilocybin services in Oregon as a delivery analog

> “The MCAP Psilocybin Program implements Ballot Measure 109 (now codified as ORS 475A), which was passed in November 2020 and directs the Oregon Health Authority to license and regulate the manufacturing, transportation, delivery, sale, and purchase of psilocybin products and the provision of psilocybin services.”

Source: [Oregon Health Authority](https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx)

> “Results indicated that in the 16 active training programs, the mean tuition was $9,359 and half offered diversity scholarships.”
> “The mean planned price for a session was $1,388 and the most common areas of specialization were trauma, mental disorders, consciousness exploration, and spirituality.”

Source: [Luoma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12304229/)

<a id="topic-2.2.2.4-11"></a>

### Psychological support delivery in a publicly funded health service

> “Oral psychedelics such as psilocybin have an acute effect evolving over 6-8 h and are generally given in combination with psychological support.”
> “In this feature, we discuss these issues and outline a model for psychological support delivery in publicly funded health services such as the National Health Service.”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41906234/)

<a id="topic-2.2.2.4-12"></a>

### Measurement-based care in major depression

> “Significantly more patients in the measurement-based care group than in the standard treatment group achieved response (86.9% compared with 62.7%) and remission (73.8% compared with 28.8%).”

Source: [Guo et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26315978/)

<a id="topic-2.2.2.4-13"></a>

### Executive Order 14401: Right to Try access and federal-state programs

> “The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a)”
> “allocate at least $50 million from existing funds to support and partner with State governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses”

Source: [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

Additional sources: [Goodwin et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37434509/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
